TS-075260 — Problem Type 2 diabetes and related metabolic disorders affect hundreds of millions of patients and are frequently accompanied by chronic inflammation, which accelerates disease progression and complications. Existing antidiabetic therapies often fail to adequately address inflammatory pathways and…

TS-075245 — Problem Although cyclin dependent kinase 9 (CDK9) is a promising drug target, traditional small-molecule inhibitors face challenges due to CDK9's structural similarities with other kinases, leading to off-target effects and limited efficacy Solution Applications Advantages Seeking opp…

TS-075233 — Problem Transducin β-like protein 1 (TBL1) has emerged as a promising therapeutic target in oncology, due to its central role in regulating multiple oncogenic signaling pathways. The challenge is how to develop a selective and effective inhibitor of TBL1 with high efficacy and limited side-eff…

TS-075183 — Problem Current eligibility biomarkers for Immune checkpoint inhibitors (ICIs) poorly predict patient’s response. Drug clearance, both at baseline and over time, is a stronger predictor of ICI effectiveness, however the current non-linear mixed effects modeling (NLME) approach for estimating …

TS-075175 — Problem Idiopathic pulmonary fibrosis (IPF) is a chronic disease where activated fibroblasts mediate the abnormal accumulation of extracellular matrix (ECM) in the lung interstitial space, leading to progressive impairment of pulmonary function. Current IPF therapies are associated with significant…

TS-062690 — Novel niclosamide analogues with improved bioavailability and mitigated dose-limiting toxicities.

TS-062685 — Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon and rectum and prostate cancers. The Need Current cancer treatments mainly rely on chemotherapy, radiation, surgery and bon…

TS-062680 — According to the American Cancer Society, breast cancer is the most common cancer for women in the US, except for skin cancer. It comprised about 30% of all new female cancers each year. While breast cancer death rates have decreased over the last several decades, it remains the second leading cause…

TS-062605 — The Need: Castration-resistant prostate cancer (CRPC) poses a significant challenge in oncology, with existing therapies often leading to resistance and disease progression. Key drivers of resistance include the androgen receptor (AR) and aldo-keto reductase family 1 member C3 (AKR1C3). Novel treat…

TS-050220 — Novel natural products and derivatives thereof that exhibit potent in vitro and in vivo activity